+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Type 2 Diabetes Market 2023-2027

  • PDF Icon

    Report

  • 120 Pages
  • November 2022
  • Region: Global
  • TechNavio
  • ID: 5351696
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The type 2 diabetes market is poised to grow by $39.37 billion during 2023-2027, accelerating at a CAGR of 10.94% during the forecast period. The market is driven by the rising prevalence of diabetes, irse in prevalence of obesity and changing lifestyles, and recent product approvals.

This report on the type 2 diabetes market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment.

The type 2 diabetes market is segmented as below:

By Drug Class

  • Insulin
  • DPP-4 inhibitor
  • GLP-1 receptor agonists
  • SGLT-2 inhibitors
  • Others

By Distribution Channel

  • Retail pharmacies
  • Hospital pharmacies
  • Online pharmacies

By Geography

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)
This study identifies the growing geriatric population as one of the prime reasons driving the type 2 diabetes market growth during the next few years. Also, an increase in awareness of diabetes and growth initiatives and innovations in therapies will lead to sizable demand in the market.

This report on the type 2 diabetes market covers the following areas:

  • Type 2 diabetes market sizing
  • Type 2 diabetes market forecast
  • Type 2 diabetes market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading type 2 diabetes market vendors that include Amgen Inc., AstraZeneca Plc, Baxter International Inc., Biocon Ltd., Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Ltd., Daiichi Sankyo Co. Ltd., DM Pharma Marketing Pvt. Ltd., Eli Lilly and Co., GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Johnson and Johnson, Merck KGaA, Novartis AG, Novo Nordisk AS, Pfizer Inc., Practo Technologies Pvt. Ltd., Sanofi SA, Takeda Pharmaceutical Co. Ltd., and Tonghua Dongbao Pharmaceutical Co. Ltd. Also, the type 2 diabetes market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The analyst's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary
1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market by Geography
Exhibit 05: Executive Summary - Chart on Market Segmentation by Drug Class
Exhibit 06: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape
2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics
3 Market Sizing
3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2022
3.4 Market outlook: Forecast for 2022-2027
Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ billion)
Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ billion)
Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
4 Historic Market Size
4.1 Global type 2 diabetes market 2017 - 2021
Exhibit 18: Historic Market Size - Data Table on Global type 2 diabetes market 2017 - 2021 ($ billion)
4.2 Drug class Segment Analysis 2017 - 2021
Exhibit 19: Historic Market Size - Drug class Segment 2017 - 2021 ($ billion)
4.3 Distribution channel Segment Analysis 2017 - 2021
Exhibit 20: Historic Market Size - Distribution channel Segment 2017 - 2021 ($ billion)
4.4 Geography Segment Analysis 2017 - 2021
Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ billion)
4.5 Country Segment Analysis 2017 - 2021
Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ billion)
5 Five Forces Analysis
5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2022 and 2027
6 Market Segmentation by Drug Class
6.1 Market segments
Exhibit 30: Chart on Drug Class - Market share 2022-2027 (%)
Exhibit 31: Data Table on Drug Class - Market share 2022-2027 (%)
6.2 Comparison by Drug Class
Exhibit 32: Chart on Comparison by Drug Class
Exhibit 33: Data Table on Comparison by Drug Class
6.3 Insulin - Market size and forecast 2022-2027
Exhibit 34: Chart on Insulin - Market size and forecast 2022-2027 ($ billion)
Exhibit 35: Data Table on Insulin - Market size and forecast 2022-2027 ($ billion)
Exhibit 36: Chart on Insulin - Year-over-year growth 2022-2027 (%)
Exhibit 37: Data Table on Insulin - Year-over-year growth 2022-2027 (%)
6.4 DPP-4 inhibitor - Market size and forecast 2022-2027
Exhibit 38: Chart on DPP-4 inhibitor - Market size and forecast 2022-2027 ($ billion)
Exhibit 39: Data Table on DPP-4 inhibitor - Market size and forecast 2022-2027 ($ billion)
Exhibit 40: Chart on DPP-4 inhibitor - Year-over-year growth 2022-2027 (%)
Exhibit 41: Data Table on DPP-4 inhibitor - Year-over-year growth 2022-2027 (%)
6.5 GLP-1 receptor agonists - Market size and forecast 2022-2027
Exhibit 42: Chart on GLP-1 receptor agonists - Market size and forecast 2022-2027 ($ billion)
Exhibit 43: Data Table on GLP-1 receptor agonists - Market size and forecast 2022-2027 ($ billion)
Exhibit 44: Chart on GLP-1 receptor agonists - Year-over-year growth 2022-2027 (%)
Exhibit 45: Data Table on GLP-1 receptor agonists - Year-over-year growth 2022-2027 (%)
6.6 SGLT-2 inhibitors - Market size and forecast 2022-2027
Exhibit 46: Chart on SGLT-2 inhibitors - Market size and forecast 2022-2027 ($ billion)
Exhibit 47: Data Table on SGLT-2 inhibitors - Market size and forecast 2022-2027 ($ billion)
Exhibit 48: Chart on SGLT-2 inhibitors - Year-over-year growth 2022-2027 (%)
Exhibit 49: Data Table on SGLT-2 inhibitors - Year-over-year growth 2022-2027 (%)
6.7 Others - Market size and forecast 2022-2027
Exhibit 50: Chart on Others - Market size and forecast 2022-2027 ($ billion)
Exhibit 51: Data Table on Others - Market size and forecast 2022-2027 ($ billion)
Exhibit 52: Chart on Others - Year-over-year growth 2022-2027 (%)
Exhibit 53: Data Table on Others - Year-over-year growth 2022-2027 (%)
6.8 Market opportunity by Drug Class
Exhibit 54: Market opportunity by Drug Class ($ billion)
7 Market Segmentation by Distribution Channel
7.1 Market segments
Exhibit 55: Chart on Distribution Channel - Market share 2022-2027 (%)
Exhibit 56: Data Table on Distribution Channel - Market share 2022-2027 (%)
7.2 Comparison by Distribution Channel
Exhibit 57: Chart on Comparison by Distribution Channel
Exhibit 58: Data Table on Comparison by Distribution Channel
7.3 Retail pharmacies - Market size and forecast 2022-2027
Exhibit 59: Chart on Retail pharmacies - Market size and forecast 2022-2027 ($ billion)
Exhibit 60: Data Table on Retail pharmacies - Market size and forecast 2022-2027 ($ billion)
Exhibit 61: Chart on Retail pharmacies - Year-over-year growth 2022-2027 (%)
Exhibit 62: Data Table on Retail pharmacies - Year-over-year growth 2022-2027 (%)
7.4 Hospital pharmacies - Market size and forecast 2022-2027
Exhibit 63: Chart on Hospital pharmacies - Market size and forecast 2022-2027 ($ billion)
Exhibit 64: Data Table on Hospital pharmacies - Market size and forecast 2022-2027 ($ billion)
Exhibit 65: Chart on Hospital pharmacies - Year-over-year growth 2022-2027 (%)
Exhibit 66: Data Table on Hospital pharmacies - Year-over-year growth 2022-2027 (%)
7.5 Online pharmacies - Market size and forecast 2022-2027
Exhibit 67: Chart on Online pharmacies - Market size and forecast 2022-2027 ($ billion)
Exhibit 68: Data Table on Online pharmacies - Market size and forecast 2022-2027 ($ billion)
Exhibit 69: Chart on Online pharmacies - Year-over-year growth 2022-2027 (%)
Exhibit 70: Data Table on Online pharmacies - Year-over-year growth 2022-2027 (%)
7.6 Market opportunity by Distribution Channel
Exhibit 71: Market opportunity by Distribution Channel ($ billion)
8 Customer Landscape
8.1 Customer landscape overview
Exhibit 72: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
9.1 Geographic segmentation
Exhibit 73: Chart on Market share by geography 2022-2027 (%)
Exhibit 74: Data Table on Market share by geography 2022-2027 (%)
9.2 Geographic comparison
Exhibit 75: Chart on Geographic comparison
Exhibit 76: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2022-2027
Exhibit 77: Chart on North America - Market size and forecast 2022-2027 ($ billion)
Exhibit 78: Data Table on North America - Market size and forecast 2022-2027 ($ billion)
Exhibit 79: Chart on North America - Year-over-year growth 2022-2027 (%)
Exhibit 80: Data Table on North America - Year-over-year growth 2022-2027 (%)
9.4 Europe - Market size and forecast 2022-2027
Exhibit 81: Chart on Europe - Market size and forecast 2022-2027 ($ billion)
Exhibit 82: Data Table on Europe - Market size and forecast 2022-2027 ($ billion)
Exhibit 83: Chart on Europe - Year-over-year growth 2022-2027 (%)
Exhibit 84: Data Table on Europe - Year-over-year growth 2022-2027 (%)
9.5 Asia - Market size and forecast 2022-2027
Exhibit 85: Chart on Asia - Market size and forecast 2022-2027 ($ billion)
Exhibit 86: Data Table on Asia - Market size and forecast 2022-2027 ($ billion)
Exhibit 87: Chart on Asia - Year-over-year growth 2022-2027 (%)
Exhibit 88: Data Table on Asia - Year-over-year growth 2022-2027 (%)
9.6 Rest of World (ROW) - Market size and forecast 2022-2027
Exhibit 89: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
Exhibit 90: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
Exhibit 91: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibit 92: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
9.7 US - Market size and forecast 2022-2027
Exhibit 93: Chart on US - Market size and forecast 2022-2027 ($ billion)
Exhibit 94: Data Table on US - Market size and forecast 2022-2027 ($ billion)
Exhibit 95: Chart on US - Year-over-year growth 2022-2027 (%)
Exhibit 96: Data Table on US - Year-over-year growth 2022-2027 (%)
9.8 Germany - Market size and forecast 2022-2027
Exhibit 97: Chart on Germany - Market size and forecast 2022-2027 ($ billion)
Exhibit 98: Data Table on Germany - Market size and forecast 2022-2027 ($ billion)
Exhibit 99: Chart on Germany - Year-over-year growth 2022-2027 (%)
Exhibit 100: Data Table on Germany - Year-over-year growth 2022-2027 (%)
9.9 China - Market size and forecast 2022-2027
Exhibit 101: Chart on China - Market size and forecast 2022-2027 ($ billion)
Exhibit 102: Data Table on China - Market size and forecast 2022-2027 ($ billion)
Exhibit 103: Chart on China - Year-over-year growth 2022-2027 (%)
Exhibit 104: Data Table on China - Year-over-year growth 2022-2027 (%)
9.10 UK - Market size and forecast 2022-2027
Exhibit 105: Chart on UK - Market size and forecast 2022-2027 ($ billion)
Exhibit 106: Data Table on UK - Market size and forecast 2022-2027 ($ billion)
Exhibit 107: Chart on UK - Year-over-year growth 2022-2027 (%)
Exhibit 108: Data Table on UK - Year-over-year growth 2022-2027 (%)
9.11 India - Market size and forecast 2022-2027
Exhibit 109: Chart on India - Market size and forecast 2022-2027 ($ billion)
Exhibit 110: Data Table on India - Market size and forecast 2022-2027 ($ billion)
Exhibit 111: Chart on India - Year-over-year growth 2022-2027 (%)
Exhibit 112: Data Table on India - Year-over-year growth 2022-2027 (%)
9.12 Market opportunity by geography
Exhibit 113: Market opportunity by geography ($ billion)
10 Drivers, Challenges, and Trends
10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 114: Impact of drivers and challenges in 2022 and 2027
10.4 Market trends
11 Vendor Landscape
11.1 Overview
11.2 Vendor landscape
Exhibit 115: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 116: Overview on factors of disruption
11.4 Industry risks
Exhibit 117: Impact of key risks on business
12 Vendor Analysis
12.1 Vendors covered
Exhibit 118: Vendors covered
12.2 Market positioning of vendors
Exhibit 119: Matrix on vendor position and classification
12.3 Amgen Inc.
Exhibit 120: Amgen Inc. - Overview
Exhibit 121: Amgen Inc. - Product / Service
Exhibit 122: Amgen Inc. - Key offerings
12.4 AstraZeneca Plc
Exhibit 123: AstraZeneca Plc - Overview
Exhibit 124: AstraZeneca Plc - Product / Service
Exhibit 125: AstraZeneca Plc - Key news
Exhibit 126: AstraZeneca Plc - Key offerings
12.5 Biocon Ltd.
Exhibit 127: Biocon Ltd. - Overview
Exhibit 128: Biocon Ltd. - Business segments
Exhibit 129: Biocon Ltd. - Key offerings
Exhibit 130: Biocon Ltd. - Segment focus
12.6 Boehringer Ingelheim International GmbH
Exhibit 131: Boehringer Ingelheim International GmbH - Overview
Exhibit 132: Boehringer Ingelheim International GmbH - Business segments
Exhibit 133: Boehringer Ingelheim International GmbH - Key news
Exhibit 134: Boehringer Ingelheim International GmbH - Key offerings
Exhibit 135: Boehringer Ingelheim International GmbH - Segment focus
12.7 Cadila Pharmaceuticals Ltd.
Exhibit 136: Cadila Pharmaceuticals Ltd. - Overview
Exhibit 137: Cadila Pharmaceuticals Ltd. - Product / Service
Exhibit 138: Cadila Pharmaceuticals Ltd. - Key offerings
12.8 Daiichi Sankyo Co. Ltd.
Exhibit 139: Daiichi Sankyo Co. Ltd. - Overview
Exhibit 140: Daiichi Sankyo Co. Ltd. - Business segments
Exhibit 141: Daiichi Sankyo Co. Ltd. - Key news
Exhibit 142: Daiichi Sankyo Co. Ltd. - Key offerings
Exhibit 143: Daiichi Sankyo Co. Ltd. - Segment focus
12.9 Eli Lilly and Co.
Exhibit 144: Eli Lilly and Co. - Overview
Exhibit 145: Eli Lilly and Co. - Product / Service
Exhibit 146: Eli Lilly and Co. - Key offerings
12.10 Glenmark Pharmaceuticals Ltd.
Exhibit 147: Glenmark Pharmaceuticals Ltd. - Overview
Exhibit 148: Glenmark Pharmaceuticals Ltd. - Product / Service
Exhibit 149: Glenmark Pharmaceuticals Ltd. - Key offerings
12.11 Merck KGaA
Exhibit 150: Merck KGaA - Overview
Exhibit 151: Merck KGaA - Business segments
Exhibit 152: Merck KGaA - Key news
Exhibit 153: Merck KGaA - Key offerings
Exhibit 154: Merck KGaA - Segment focus
12.12 Novartis AG
Exhibit 155: Novartis AG - Overview
Exhibit 156: Novartis AG - Business segments
Exhibit 157: Novartis AG - Key offerings
Exhibit 158: Novartis AG - Segment focus
12.13 Novo Nordisk AS
Exhibit 159: Novo Nordisk AS - Overview
Exhibit 160: Novo Nordisk AS - Business segments
Exhibit 161: Novo Nordisk AS - Key offerings
Exhibit 162: Novo Nordisk AS - Segment focus
12.14 Pfizer Inc.
Exhibit 163: Pfizer Inc. - Overview
Exhibit 164: Pfizer Inc. - Product / Service
Exhibit 165: Pfizer Inc. - Key news
Exhibit 166: Pfizer Inc. - Key offerings
12.15 Sanofi SA
Exhibit 167: Sanofi SA - Overview
Exhibit 168: Sanofi SA - Business segments
Exhibit 169: Sanofi SA - Key news
Exhibit 170: Sanofi SA - Key offerings
Exhibit 171: Sanofi SA - Segment focus
12.16 Takeda Pharmaceutical Co. Ltd.
Exhibit 172: Takeda Pharmaceutical Co. Ltd. - Overview
Exhibit 173: Takeda Pharmaceutical Co. Ltd. - Product / Service
Exhibit 174: Takeda Pharmaceutical Co. Ltd. - Key news
Exhibit 175: Takeda Pharmaceutical Co. Ltd. - Key offerings
12.17 Tonghua Dongbao Pharmaceutical Co. Ltd.
Exhibit 176: Tonghua Dongbao Pharmaceutical Co. Ltd. - Overview
Exhibit 177: Tonghua Dongbao Pharmaceutical Co. Ltd. - Product / Service
Exhibit 178: Tonghua Dongbao Pharmaceutical Co. Ltd. - Key offerings
13 Appendix
13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 179: Inclusions checklist
Exhibit 180: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 181: Currency conversion rates for US$
13.4 Research methodology
Exhibit 182: Research methodology
Exhibit 183: Validation techniques employed for market sizing
Exhibit 184: Information sources
13.5 List of abbreviations
Exhibit 185: List of abbreviations

Executive Summary

The analyst recognizes the following companies as the key players in the global type 2 diabetes market: Amgen Inc., AstraZeneca Plc, Baxter International Inc., Biocon Ltd., Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Ltd., Daiichi Sankyo Co. Ltd., DM Pharma Marketing Pvt. Ltd., Eli Lilly and Co., GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Johnson and Johnson, Merck KGaA, Novartis AG, Novo Nordisk AS, Pfizer Inc., Practo Technologies Pvt. Ltd., Sanofi SA, Takeda Pharmaceutical Co. Ltd., and Tonghua Dongbao Pharmaceutical Co. Ltd.

Commenting on the report, one of the report's analysts said: 'The latest trend gaining momentum in the market is the growing geriatric population.'

According to the report, one of the major drivers for this market is the rising prevalence of diabetes.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Amgen Inc.
  • AstraZeneca Plc
  • Baxter International Inc.
  • Biocon Ltd.
  • Boehringer Ingelheim International GmbH
  • Cadila Pharmaceuticals Ltd.
  • Daiichi Sankyo Co. Ltd.
  • DM Pharma Marketing Pvt. Ltd.
  • Eli Lilly and Co.
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd.
  • Johnson and Johnson
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk AS
  • Pfizer Inc.
  • Practo Technologies Pvt. Ltd.
  • Sanofi SA
  • Takeda Pharmaceutical Co. Ltd.
  • Tonghua Dongbao Pharmaceutical Co. Ltd.